HC
IGC icon

Hurley Capital’s IGC Pharma IGC Stock Holding History

Hurley Capital’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
100
– – ﹤0.01% 670
2026
Q1 		$26 Hold
100
– – ﹤0.01% 658
2025
Q4 		$28 Hold
100
– – ﹤0.01% 586
2025
Q3 		$42 Hold
100
– – ﹤0.01% 684
2025
Q2 		$31 Hold
100
– – ﹤0.01% 459
2025
Q1 		$29 Hold
100
– – ﹤0.01% 495
2024
Q4 		$36 Buy
+100
New +$37 ﹤0.01% 401

Other funds holding IGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LC
Lawood & Co Williamsport, Pennsylvania $148M AUM

Hurley Capital's IGC Position: Q2 2026 in Review

Hurley Capital held its IGC Pharma (IGC) position steady in Q2 2026 at 100 shares worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Hurley Capital first reported a position in IGC in Q4 2024 and has held it in 7 quarters since. The position peaked at $42 in Q3 2025. 36 funds tracked by Wall St. Rank hold IGC as of Q2 2026.

  • Hurley Capital held 100 shares of IGC Pharma worth $27 as of Q2 2026.
  • Hurley Capital left its IGC Pharma share count unchanged in Q2 2026.
  • IGC Pharma made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #670 holding.
  • Hurley Capital first reported a position in IGC Pharma in Q4 2024 and has held it in 7 quarters since.
  • Hurley Capital's IGC Pharma position peaked at $42 in Q3 2025.
  • 36 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.